Company intelligence / Profile preview

Cytobiologics

Rangareddy/Hyderabad*, Telangana, Indiain.linkedin.com ↗

Ownership: Private
Development stage: Commercial

Overview

Cytobiologics is an active multinational healthcare company specializing in the development and manufacturing of plasma-derived therapies and medical devices. It serves as the sole marketing business for Promea Therapeutics’ Plasma Derivatives Manufacturing Unit (PDMU), with a mission to improve global health through innovative life science solutions. The company has demonstrated significant financial growth since its founding in India in 2021.

Modalities: Plasma-derived therapiesMedical devices
Industry: Biotech

Drug pipeline

2 assets

ImmuPro

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

Promea Therapeutics

Beyond the preview

Go deeper on Cytobiologics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cytobiologics.

Explore the full profile